Clinical Trial Update: ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years

View source ↗

Summary

The ReAHEAD trial, a Boehringer Ingelheim study in atrial fibrillation patients under 75, evaluated whether education improves adherence to dabigatran; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dabigatran (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Status: COMPLETED | Results posted: 2024-09-19